Wang F, Li S, Wang T Y, Lopez G A, Antoshechkin I, Chou T F
Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Proteome Exploration Laboratory, Beckman Institute, California Institute of Technology, Pasadena, CA 91125, USA.
Brain Commun. 2022 Jul 6;4(4):fcac176. doi: 10.1093/braincomms/fcac176. eCollection 2022.
Mutations in p97/VCP cause two motor neuron diseases: inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia and familial amyotrophic lateral sclerosis. How p97 mutations lead to motor neuron degeneration is, however, unknown. Here we used patient-derived induced pluripotent stem cells to generate p97 mutant motor neurons. We reduced the genetic background variation by comparing mutant motor neurons to its isogenic wild type lines. Proteomic analysis reveals that p97 motor neurons upregulate several cell cycle proteins at Day 14, but this effect diminishes by Day 20. Molecular changes linked to delayed cell cycle exit are observed in p97 mutant motor neurons. We also find that two p97 inhibitors, CB-5083 and NMS-873, restore some dysregulated protein levels. In addition, two p97 inhibitors and a food and drug administration-approved cyclin-dependent kinase 4/6 inhibitor, Abemaciclib, can rescue motor neuron death. Overall, we successfully used iPSC-derived motor neurons, identified dysregulated proteome and transcriptome and showed that p97 inhibitors rescue phenotypes in this disease model.
p97/VCP基因的突变会引发两种运动神经元疾病:与骨Paget病和额颞叶痴呆相关的包涵体肌病以及家族性肌萎缩侧索硬化症。然而,p97突变如何导致运动神经元变性尚不清楚。在此,我们利用患者来源的诱导多能干细胞生成p97突变运动神经元。通过将突变运动神经元与其同基因野生型细胞系进行比较,我们减少了遗传背景差异。蛋白质组学分析显示,p97运动神经元在第14天会上调几种细胞周期蛋白,但这种效应在第20天时会减弱。在p97突变运动神经元中观察到与细胞周期退出延迟相关的分子变化。我们还发现,两种p97抑制剂CB - 5083和NMS - 873可恢复一些失调的蛋白质水平。此外,两种p97抑制剂和一种美国食品药品监督管理局批准的细胞周期蛋白依赖性激酶4/6抑制剂阿贝西利可挽救运动神经元死亡。总体而言,我们成功利用诱导多能干细胞来源的运动神经元,鉴定出失调的蛋白质组和转录组,并表明p97抑制剂可在该疾病模型中挽救表型。